A comparison of two blood thinners (Kengrexal and Brilique) for rapid inhibition of platelets in patients with suspected heart attack

Phase 1

• Conditions: ST-elevation Myocardial Infarction; MedDRA version: 20.0 Level: LLT Classification code 10064345 Term: ST segment elevation myocardial infarction System Organ Class: 100000004849; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2016-003721-41-DK
• Lead Sponsor: Department of Cardiology, Aarhus University Hospital, Skejby

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-09
• Last Update Posted: 10 December 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

1) Patients triaged for PPCI due to suspicion of STEMI.
2) Symptom duration < 12 hours
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

1.Age below 18 years or above 90 years
2.Previous inclusion in the study
3.Transportation time to PCI-centre < 30 minutes
4.Already in treatment with ticagrelor, prasugrel or clopidogrel
5.Treatment with oral anticoagulants (warfarin, coumarins, rivaroxaban, apixaban, dabigatran)
6.Adjunctive use of glycoprotein IIb/IIIa inhibitor during PCI
7.Active bleeding
8.Known, severe kidney failure (GFR < 30 ml/min) and/or liver disease
9.Women of child bearing ability who are not using contraceptive medication
10. Severe mental or psychiatric disease, altered mental state (including unconsciousness) making it impossible to achieve informed consent

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified